eLetters is an online forum for ongoing peer review. Submission of eLetters are open to all. Please read our Terms of Service before submitting your own eLetter.
Research ArticleCancer
Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAFV600E melanoma
- Siwen Hu-Lieskovan1,
- Stephen Mok1,
- Blanca Homet Moreno1,2,
- Jennifer Tsoi3,4,
- Lidia Robert1,
- Lucas Goedert1,
- Elaine M. Pinheiro5,
- Richard C. Koya1,*,
- Thomas G. Graeber3,4,6,
- Begoña Comin-Anduix6,7 and
- Antoni Ribas1,4,6,7,†
- 1Division of Hematology-Oncology, Department of Medicine, University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA.
- 2Division of Translational Oncology, Carlos III Health Institute, Madrid 28029, Spain.
- 3Crump Institute for Molecular Imaging, UCLA, Los Angeles, CA 90095, USA.
- 4Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, CA 90095, USA.
- 5Merck Research Laboratories, Boston, MA 02115, USA.
- 6Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, CA 90095, USA.
- 7Division of Surgical Oncology, Department of Surgery, UCLA, Los Angeles, CA 90095, USA.
- ↵†Corresponding author. E-mail: aribas{at}mednet.ucla.edu
↵* Present address: Department of Immunology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA.
See allHide authors and affiliations
Science Translational Medicine 18 Mar 2015:
Vol. 7, Issue 279, pp. 279ra41
DOI: 10.1126/scitranslmed.aaa4691
Vol. 7, Issue 279, pp. 279ra41
DOI: 10.1126/scitranslmed.aaa4691
Siwen Hu-Lieskovan
1Division of Hematology-Oncology, Department of Medicine, University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA.
Stephen Mok
1Division of Hematology-Oncology, Department of Medicine, University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA.
Blanca Homet Moreno
1Division of Hematology-Oncology, Department of Medicine, University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA.
2Division of Translational Oncology, Carlos III Health Institute, Madrid 28029, Spain.
Jennifer Tsoi
3Crump Institute for Molecular Imaging, UCLA, Los Angeles, CA 90095, USA.
4Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, CA 90095, USA.
Lidia Robert
1Division of Hematology-Oncology, Department of Medicine, University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA.
Lucas Goedert
1Division of Hematology-Oncology, Department of Medicine, University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA.
Elaine M. Pinheiro
5Merck Research Laboratories, Boston, MA 02115, USA.
Richard C. Koya
1Division of Hematology-Oncology, Department of Medicine, University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA.
Thomas G. Graeber
3Crump Institute for Molecular Imaging, UCLA, Los Angeles, CA 90095, USA.
4Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, CA 90095, USA.
6Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, CA 90095, USA.
Begoña Comin-Anduix
6Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, CA 90095, USA.
7Division of Surgical Oncology, Department of Surgery, UCLA, Los Angeles, CA 90095, USA.
Antoni Ribas
1Division of Hematology-Oncology, Department of Medicine, University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA.
4Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, CA 90095, USA.
6Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, CA 90095, USA.
7Division of Surgical Oncology, Department of Surgery, UCLA, Los Angeles, CA 90095, USA.
Submit a Response to This Article
No eLetters have been published for this article.